Allogene Therapeutics (ALLO) Other Non-Current Liabilities (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Other Non-Current Liabilities data on file, last reported at $16.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 42.97% year-over-year to $16.1 million; the trailing twelve-month figure through Mar 2026 stood at $16.1 million (up 42.97% YoY), and the FY2025 full-year result was $15.8 million, up 103.63% from the prior year.
• Other Non-Current Liabilities improved to $16.1 million in Q1 2026, from $15.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $16.1 million in Q1 2026 to a low of $5.2 million in Q1 2024.
• A 5-year average of $8.7 million and a median of $7.2 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities surged 156.93% in 2022 and retreated 27.42% in 2023, its largest moves.
• Tracing ALLO's Other Non-Current Liabilities over 5 years: stood at $5.8 million in 2022, then declined by 11.42% to $5.2 million in 2023, then surged by 49.86% to $7.8 million in 2024, then jumped by 103.63% to $15.8 million in 2025, then grew by 2.0% to $16.1 million in 2026.
• Business Quant data shows ALLO's Other Non-Current Liabilities at $16.1 million in Q1 2026, $15.8 million in Q4 2025, and $15.5 million in Q3 2025.